A 2-year-old male with chronic kidney disease with secondary hyperparathyroidism developed hypercal - cemia while receiving calcitriol, without achieving a serum parathyroid hormone concentration within the goal range. Cinacalcet 15 mg (1.2 mg/kg), crushed and administered via gastrostomy tube, was added to the patient’s therapy. This therapy was effective in achieving targeted laboratory parameters in our patient despite instructions in the prescribing information that cinacalcet should always be taken whole
Cinacalcet HCl: A novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney diseas...
Introduction — Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney diseas...
Abstract • Introduction In the treatment of secondary hyperparathyroidism (2HPT) of chronic kidney...
A 2-year-old male with chronic kidney disease with secondary hyperparathyroidism developed hypercalc...
Introduction: Therapy with vitamin D3 analogs suppress the parathyroid hormone (PTH) secretion in ch...
BACKGROUND: Treatment of secondary hyperparathyroidism with vitamin D and calcium in patients receiv...
Background Secondary hyperparathyroidism (SHPT) is a common complication in chronic kidney disease (...
Background: Secondary hyperparathyroidism a common consequence of chronic kidney disease is associat...
Abstract Introduction: Secondary hyperparathyroidism is the target of several therapeutic strategie...
Background: secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease ...
Background: This randomized phase 3 study evaluated the efficacy and safety of cinacalcet in childre...
The effects of cinacalcet in persistent and/or hypercalcaemia-associated secondary hyperparathyroidi...
Secondary hyperparathyroidism (SHPT) is an important complication of advanced chronic kidney disease...
Secondary hyperparathyroidism (SHPT) is an important complication of advanced chronic kidney disease...
Introduction Secondary hyperparathyroidism (SHPT) develops in patients with chronic renal failure. C...
Cinacalcet HCl: A novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney diseas...
Introduction — Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney diseas...
Abstract • Introduction In the treatment of secondary hyperparathyroidism (2HPT) of chronic kidney...
A 2-year-old male with chronic kidney disease with secondary hyperparathyroidism developed hypercalc...
Introduction: Therapy with vitamin D3 analogs suppress the parathyroid hormone (PTH) secretion in ch...
BACKGROUND: Treatment of secondary hyperparathyroidism with vitamin D and calcium in patients receiv...
Background Secondary hyperparathyroidism (SHPT) is a common complication in chronic kidney disease (...
Background: Secondary hyperparathyroidism a common consequence of chronic kidney disease is associat...
Abstract Introduction: Secondary hyperparathyroidism is the target of several therapeutic strategie...
Background: secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease ...
Background: This randomized phase 3 study evaluated the efficacy and safety of cinacalcet in childre...
The effects of cinacalcet in persistent and/or hypercalcaemia-associated secondary hyperparathyroidi...
Secondary hyperparathyroidism (SHPT) is an important complication of advanced chronic kidney disease...
Secondary hyperparathyroidism (SHPT) is an important complication of advanced chronic kidney disease...
Introduction Secondary hyperparathyroidism (SHPT) develops in patients with chronic renal failure. C...
Cinacalcet HCl: A novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney diseas...
Introduction — Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney diseas...
Abstract • Introduction In the treatment of secondary hyperparathyroidism (2HPT) of chronic kidney...